A Phase 3 Randomized Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.